Compare Icl Group Ltd (ICL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Sanofi SA — how do they compare? Icl Group Ltd trades at $5.46 (market cap $6.94B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 15× Icl Group Ltd's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ICL | SNY | |
|---|---|---|
Market Cap | $6.94B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $52.34 |
52-Week Low | $4.80 | $41.33 |
Enterprise Value | $9.58B | $124.19B |
Dividend Yield | 3.86% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.455, up 2.15% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.12 per share, beating estimates, and announced a cost-transformation program. Revenue for 2025 was $7.15 billion, with a net income margin of 3.95%. The stock has a P/E ratio of 22.25 and an EV/EBITDA of 7.02.
Outlook is mixed; earnings beats and operational improvements support upside, but analyst consensus is entirely Hold, reflecting valuation concerns. Key risks include raw material cost volatility and foreign exchange headwinds. The stock offers a dividend yield but faces margin pressure from declining profitability trends.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
